메디코스바이오텍 is developing wound treatments that use spider silk protein targeted at hard-to-heal wounds. The company has secured a significant investment and is partnering with a U.S. firm to enter the American market. Its immediate plan is to develop the candidate through U.S. regulatory pathways and pursue FDA approval and launch. To execute this, the company and its partner will establish a U.S. joint venture. The articles do not disclose revenue, users, or other operating metrics. The investment is intended to support product development and regulatory activities in the U.S.

Total raised

$7M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2024